Nadofaragene firadenovec

Unassigned

New Medicines

Adstiladrin · High-grade non-muscle invasive bladder cancer (NMIBC) in patients who are BCG unresponsive

Information

Adstiladrin
Advanced therapy medicinal product (ATMP)
Ferring
Ferring

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A non-replicating adenovirus vector harboring the human IFN alpha2b gene. When combined with the excipient Syn3, intravesical administration of the rAd-IFN results in transduction of the virus into the epithelial cell lining in the bladder.
The overall incidence of bladder cancer in the UK is 11.4 per 100,000 population. At diagnosis, only about 5% of patients have metastatic disease, usually to lymph nodes, lung, liver, bone and central nervous system. Around 30% have involvement of the muscle layer. Around 70% have superficial disease, of which 10% is CIS [1].
High-grade non-muscle invasive bladder cancer (NMIBC) in patients who are BCG unresponsive
Intravesical

Evidence based evaluations

NIHR